Clinical Trial: INBRX105

Trial Status: Open
Disease Type: Solid Tumors All
Trial ID INBRX105
Sponsor ID Inhibrx

An Open-Label, Multicenter, First-in-Human Dose Escalation, Phase 1 Study of INBRX-105 and INBRX-105 in Combination with Pembrolizumab in Patients with Locally Advanced or Metastatic Solid Tumors

Locations

Fairfax Office

Learn More About This Trial

Other Relevant Trials
Trial ID 516-014
Sponsor ID Mirati

A Multicenter, Open-Label, Extension Study of the Safety and Tolerability of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Patients with Advanced or Metastatic Solid Malignancies

Trial ID JBI-802-101
Sponsor ID Jubilant Therapeutics

A First-in-Human, Open-Label, Dose Escalation and Expansion Study of Orally Administered JBI-802 in Patients with Advanced Solid Tumors